(Q38377286)

2 September 2017

1 reference

title

The challenge of controlling phosphorus in chronic kidney disease (English)

1 reference

2 September 2017

author name string

Jorge B Cannata-Andía

series ordinal

1

1 reference

2 September 2017

Kevin J Martin

series ordinal

2

1 reference

2 September 2017

language of work or name

English

0 references

publication date

13 March 2015

1 reference

Nephrology Dialysis Transplantation

2 September 2017

published in

1 reference

2 September 2017

volume

31

1 reference

2 September 2017

issue

4

1 reference

2 September 2017

page(s)

541-547

1 reference

50 years of research and discovery in chronic kidney disease and mineral & bone disorder: the central role of phosphate

2 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFV055

Serum iPTH, calcium and phosphate, and the risk of mortality in a European haemodialysis population

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFV055

Phosphorus and survival: key questions that need answers

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFV055

Phosphate may promote CKD progression and attenuate renoprotective effect of ACE inhibition

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFV055

Serum levels of phosphorus, parathyroid hormone, and calcium and risks of death and cardiovascular disease in individuals with chronic kidney disease: a systematic review and meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFV055

Serum phosphate levels and risk of infection in incident dialysis patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFV055

High phosphorus diet induces vascular calcification, a related decrease in bone mass and changes in the aortic gene expression

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFV055

Cardiovascular risk factors in chronic kidney disease: does phosphate qualify?

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFV055

High dietary phosphate intake reduces bone strength in the growing rat skeleton.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFV055

Serum phosphorus concentrations and arterial stiffness among individuals with normal kidney function to moderate kidney disease in MESA

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFV055

High phosphate directly affects endothelial function by downregulating annexin II.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFV055

Serum phosphorus levels associate with coronary atherosclerosis in young adults

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFV055

Association of serum phosphate with vascular and valvular calcification in moderate CKD.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFV055

Oral calcium carbonate affects calcium but not phosphorus balance in stage 3-4 chronic kidney disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFV055

Elevated extracellular calcium levels induce smooth muscle cell matrix mineralization in vitro

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFV055

Update on fibroblast growth factor 23 in chronic kidney disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFV055

Mineral metabolism, mortality, and morbidity in maintenance hemodialysis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFV055

Vascular calcification mechanisms

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFV055

Role of the sodium-dependent phosphate cotransporter, Pit-1, in vascular smooth muscle cell calcification

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFV055

The connections between vascular calcification and bone health

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFV055

BMP-7 is an efficacious treatment of vascular calcification in a murine model of atherosclerosis and chronic renal failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFV055

Vascular calcification and cardiovascular function in chronic kidney disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFV055

Coronary artery, aortic wall, and valvular calcification in nondialyzed individuals with type 2 diabetes and renal disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFV055

Fibroblast growth factor-23 (FGF-23) is independently correlated to aortic calcification in haemodialysis patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFV055

Fibroblast growth factor-23 and cardiovascular events in CKD.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFV055

Effects of phosphate binders in moderate CKD

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFV055

Vegetarian compared with meat dietary protein source and phosphorus homeostasis in chronic kidney disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFV055

Responsiveness of FGF-23 and mineral metabolism to altered dietary phosphate intake in chronic kidney disease (CKD): results of a randomized trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFV055

Phosphate homeostasis in CKD: report of a scientific symposium sponsored by the National Kidney Foundation

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFV055

Sevelamer attenuates the progression of coronary and aortic calcification in hemodialysis patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFV055

Sevelamer versus calcium carbonate in incident hemodialysis patients: results of an open-label 24-month randomized clinical trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFV055

Effect of lanthanum carbonate treatment on bone in Japanese dialysis patients with hyperphosphatemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFV055

Effect of calcium-based versus non-calcium-based phosphate binders on mortality in patients with chronic kidney disease: an updated systematic review and meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFV055

Evaluation of calcium acetate/magnesium carbonate as a phosphate binder compared with sevelamer hydrochloride in haemodialysis patients: a controlled randomized study (CALMAG study) assessing efficacy and tolerability

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFV055

A comparison of calcium acetate/magnesium carbonate and sevelamer-hydrochloride effects on fibroblast growth factor-23 and bone markers: post hoc evaluation from a controlled, randomized study

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFV055

Randomized clinical trial of the iron-based phosphate binder PA21 in hemodialysis patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFV055

Ferric citrate controls phosphorus and delivers iron in patients on dialysis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFV055

Coupling fibroblast growth factor 23 production and cleavage: iron deficiency, rickets, and kidney disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFV055

A comparative review of the efficacy and safety of established phosphate binders: calcium, sevelamer, and lanthanum carbonate

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFV055

Phosphate Binders and Clinical Outcomes in Patients with Stage 5D Chronic Kidney Disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFV055

AMG 416 (velcalcetide) is a novel peptide for the treatment of secondary hyperparathyroidism in a single-dose study in hemodialysis patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFV055

Effects of sevelamer and calcium-based phosphate binders on mortality in hemodialysis patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFV055

Mortality in kidney disease patients treated with phosphate binders: a randomized study

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFV055

Use of phosphate-binding agents is associated with a lower risk of mortality

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFV055

21 January 2018

Identifiers

DOI

10.1093/NDT/GFV055

1 reference

release_vl36olrw5zbo5dht5rqxjhce4q

2 September 2017

Fatcat ID

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/vl36olrw5zbo5dht5rqxjhce4q

mapped directly with Wikidata item

24 November 2022

based on heuristic

1 reference